Attention medical professionals! Changes have been made to the Instructions for the use of the drug Ofloxacin infusion solution.
27.04.2016
Attention medical professionals! Changes have been made to the Instructions for the use of the drug Ofloxacin infusion solution.
For the attention of medical professionals: In March 2016, a new Instruction for the medical use of the drug Ofloxacin infusion solution 2 mg/ml was approved.
The new information about the drug is based on current data regarding its effectiveness and safety, as well as clinical use experience. Changes have been made to all sections of the Instruction.
According to the pharmacological properties, clinical application spectrum, and safety profile, the Ofloxacin drug produced by JSC "Kraspharma"*corresponds to the originator drug Tarivid infusion solution**.
You can find the detailed new instruction for use on the product page in the Product Catalog.
The new information about the drug is based on current data regarding its effectiveness and safety, as well as clinical use experience. Changes have been made to all sections of the Instruction.
According to the pharmacological properties, clinical application spectrum, and safety profile, the Ofloxacin drug produced by JSC "Kraspharma"*corresponds to the originator drug Tarivid infusion solution**.
You can find the detailed new instruction for use on the product page in the Product Catalog.
